Published in Science on November 25, 1966
Cellular recognition by mouse lymphocytes in vitro. I. Definition of a new technique and results of stimulation by phytohemagglutinin and specific antigens. J Exp Med (1970) 3.55
Solubilization and partial characterization of a phytohemagglutinin receptor site from human erythrocytes. Proc Natl Acad Sci U S A (1969) 1.47
Immunological studies of phytohaemagglutinin. I. Reaction between phytohaemagglutinin and normal sera. Immunology (1968) 1.44
Genetic control of thymus-derived cell function. I. In vitro DNA synthetic response of normal mouse spleen cells stimulated by the mitogens concanavalin A and phytohemagglutinin. J Exp Med (1972) 0.99
Precipitation of serum proteins by phytohaemagglutinin. Clin Exp Immunol (1971) 0.89
Isolation and Characterization of Factors in Sweet Potato Root Which Agglutinate Germinated Spores of Ceratocystis fimbriata, Black Rot Fungus. Plant Physiol (1978) 0.85
The effect of N-acetyl-D-galactosamine and amantadine hydrochloride on equine lymphocytes stimulated with phytohemagglutinin. J Cell Biol (1969) 0.79
Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol (1996) 5.40
Studies on lysosomes. XI. Characterization of a hydrolase-rich fraction from human lymphocytes. J Cell Biol (1968) 4.22
SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med (1998) 4.18
Purification and properties of bacteriophage T4-induced RNA ligase. Proc Natl Acad Sci U S A (1972) 4.18
The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol (1988) 3.69
Isolation of a cDNA for human acid alpha-glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients. Proc Natl Acad Sci U S A (1986) 3.49
Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med (1985) 3.33
Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage). Cancer (1975) 3.26
Lymphocytes: circulation altered by trypsin. Science (1968) 2.99
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A (1978) 2.78
The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature (1988) 2.66
Sialic acid binding sites: role in hemagglutination by Mycoplasma gallisepticum. Science (1966) 2.62
Studies on ribonucleic acid ligase. Characterization of an adenosine triphosphate-inorganic pyrophosphate exchange reaction and demonstration of an enzyme-adenylate complex with T4 bacteriophage-induced enzyme. J Biol Chem (1974) 2.44
Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med (1975) 2.35
Studies of PPLO infection. II. The neurotoxin of Mycoplasma neurolyticum. J Exp Med (1966) 2.34
Effect of cyclic 3',5'-adenosine monophosphate and theophylline on lymphocyte transformation. Proc Soc Exp Biol Med (1970) 2.30
Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med (1983) 2.18
DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science (1989) 2.11
Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med (1976) 2.04
Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol (1985) 1.96
Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg (1992) 1.92
Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res (1993) 1.88
Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci U S A (1985) 1.87
Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol (1992) 1.84
Patient transfers: medical practice as social triage. Am J Public Health (1984) 1.83
Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest (1986) 1.76
Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med (1997) 1.75
Studies on the lymphocyte 5'-nucleotidase in chronic lymphocytic leukemia, infectious mononucleosis, normal subpopulations, and phytohemagglutinin-stimulated cells. Cancer Res (1974) 1.74
The effect of N acetyl C-galactosamine and other sugars on the mitogenic activity and attachment of PHA to tonsil cells. Blood (1968) 1.73
Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A- and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery. Crit Care Med (1999) 1.64
Studies on lysosomes. XII. Redistribution of acid hydrolases in human lymphocytes stimulated by phytohemagglutinin. J Cell Biol (1968) 1.58
Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg (1999) 1.54
Selection of the optimum surgical treatment of stage I melanoma by depth of microinvasion: Use of the combined microstage technique (Clark-Breslow). Ann Surg (1975) 1.52
Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme. J Clin Invest (1979) 1.50
Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet (1975) 1.50
Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet (1994) 1.49
Evidence for control of several different tissue-specific isozymes of adenosine deaminase by a single genetic locus. Nat New Biol (1973) 1.48
Studies on the regulation of one-carbon metabolism. II. Repression-derepression of serine hydroxymethyltransferase by methionine in Escherichia coli 113-3. J Biol Chem (1972) 1.42
DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res (1989) 1.40
The role of vitamin E deficiency in the abnormal autohemolysis of acanthocytosis. Trans Assoc Am Physicians (1965) 1.39
Lymphocyte plasma membranes: analysis of proteins and glycoproteins by SDS-gel electrophoresis. Blood (1973) 1.38
A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII). Hum Mol Genet (1994) 1.35
Appearance of hydrolase rich granules in human lymphocytes induced by phytohemagglutinin and antigens. Blood (1967) 1.35
p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood (1993) 1.34
Amerioration of neurologic abnormalities after "enzyme replacement" in adenosine deaminase deficiency. N Engl J Med (1980) 1.32
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res (1989) 1.31
Template activity of nuclei from stimulated lymphocytes. Nature (1969) 1.31
Confirmation of the regional localization of the genes for human acid alpha-glucosidase (GAA) and adenosine deaminase (ADA) by somatic cell hybridization. Ann Hum Genet (1984) 1.28
Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med (1987) 1.27
Biostatistical basis of elective node dissection for malignant melanoma. Ann Surg (1977) 1.27
Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene (1996) 1.26
Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations. J Clin Invest (1976) 1.25
Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest (1981) 1.25
Stimulation of human tonsillar lymphocytes in vitro. Clin Exp Immunol (1966) 1.23
Adenosine-deaminase deficiency in a child diagnosed prenatally. Lancet (1975) 1.22
Full genome sequence of a peste des petits ruminants virus (PPRV) from Ghana. Virus Genes (2014) 1.22
Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res (1991) 1.22
Medical care and mortality: racial differences in preventable deaths. Int J Health Serv (1985) 1.18
Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1987) 1.18
Adenosine promotes neutrophil chemotaxis. J Exp Med (1988) 1.18
Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbor a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1- murine lymphoma mutants. J Biol Chem (1992) 1.17
Alterations in isozymes of adenosine deaminase during stimulation of human peripheral blood lymphocytes. Cell Immunol (1974) 1.15
Characterization of residual enzyme activity in fibroblasts from patients with adenosine deaminase deficiency and combined immunodeficiency: evidence for a mutant enzyme. Proc Natl Acad Sci U S A (1976) 1.15
Studies of the Rous sarcoma virus RNA: characterization of the 5'-terminus. Biochem Biophys Res Commun (1973) 1.15
Heterogeneity of 5'-nucleotidase activity in lymphocytes in chronic lymphocytic leukemia. J Clin Invest (1973) 1.14
Identification and characterization of nine RFLPs at the adenosine deaminase (ADA) locus. Am J Hum Genet (1989) 1.14
SCID in Jack Russell terriers: a new animal model of DNA-PKcs deficiency. J Immunol (2001) 1.13
Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol (1995) 1.13
Genetic heterogeneity in partial adenosine deaminase deficiency. J Clin Invest (1983) 1.12
Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Biochem J (1988) 1.12
Acid alpha-glucosidase: a new polymorphism in man demonstrable by 'affinity' electrophoresis. Ann Hum Genet (1975) 1.12
Engagement of adenosine receptors inhibits hydrogen peroxide (H2O2-) release by activated human neutrophils. Clin Immunol Immunopathol (1987) 1.11
Plasma deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in an adenosine deaminase-deficient child. J Clin Invest (1980) 1.10
Studies of lysosomes. 8. The effect of polyene antibiotics on lysosomes. Biochem Pharmacol (1967) 1.10
Conversion of human erythrocyte-adenosine deaminase activity to different tissue-specific isozymes. Evidence for a common catalytic unit. J Clin Invest (1975) 1.10
The effect of epsilon amino caproic acid and other inhibitors of proteolysis upon the response of human peripheral blood lymphocytes to phytohemagglutinin. J Clin Invest (1971) 1.09
Adenosine deaminase deficiency without immunodeficiency: clinical and metabolic studies. Pediatr Res (1980) 1.08
Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J Pathol (1985) 1.08
Human lymphocytes: 5'-nucleotidase-positive and -negative subpopulations. J Clin Invest (1975) 1.07
Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci U S A (1995) 1.07
A genetic linkage map of chromosome 17. Genomics (1990) 1.05
Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest (1998) 1.05
Differences in the behavior of the membrane and membrane-associated filamentous structures in normal and chronic lymphocytic leukemia (CLL) lymphocytes. J Immunol (1979) 1.04
Letter: Severe combined immunodeficiency and adenosine-deaminase deficiency. Lancet (1973) 1.04
Multifocal extremity sarcoma: an uncommon and controversial entity. Ann Surg Oncol (1998) 1.04
Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype. Biochem Biophys Res Commun (1998) 1.02
Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase: overview, genetic heterogeneity and therapy. Birth Defects Orig Artic Ser (1983) 1.01
Spur-shaped erythrocytes in Laennec's cirrhosis. N Engl J Med (1966) 1.01
Immunologic sequelae of thermal injury. Ann N Y Acad Sci (1968) 1.00
Function of 5'-nucleotidase in the uptake of adenosine from AMP by human lymphocytes. J Biol Chem (1975) 0.99
Regulatory mechanisms in the human leukocyte. I. The feedback control of deoxycytidylate deaminase. Blood (1967) 0.99
Further characterization of SacI RFLPs at the acid alpha glucosidase (GAA) locus. Nucleic Acids Res (1990) 0.99
Identification of a missense mutation in one allele of a patient with Pompe disease, and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele. Am J Hum Genet (1991) 0.99
THE "INDUCTION" OF DIHYDROFOLIC REDUCTASE ACTIVITY IN LEUKOCYTES AND ERYTHROCYTES OF PATIENTS TREATED WITH AMETHOPTERIN. J Clin Invest (1963) 0.99
RNA metabolism in normal and leukaemic leucocytes: further studies on RNA synthesis. Br J Haematol (1968) 0.99
Nucleoside deaminase: an enzymatic marker for stress erythropoiesis in the mouse. J Clin Invest (1970) 0.98
In vivo and in vitro effects of thymosin and adenosine deaminase on adenosine-deaminase-deficient lymphocytes. N Engl J Med (1979) 0.98